Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Accounts Payables: 2017-2025

Historic Accounts Payables for Puma Biotechnology (PBYI) over the last 9 years, with Sep 2025 value amounting to $6.4 million.

  • Puma Biotechnology's Accounts Payables fell 14.96% to $6.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.4 million, marking a year-over-year decrease of 14.96%. This contributed to the annual value of $5.5 million for FY2024, which is 20.03% down from last year.
  • As of Q3 2025, Puma Biotechnology's Accounts Payables stood at $6.4 million, which was up 17.74% from $5.4 million recorded in Q2 2025.
  • Puma Biotechnology's 5-year Accounts Payables high stood at $20.0 million for Q3 2021, and its period low was $5.1 million during Q3 2023.
  • Over the past 3 years, Puma Biotechnology's median Accounts Payables value was $6.9 million (recorded in 2023), while the average stood at $7.4 million.
  • In the last 5 years, Puma Biotechnology's Accounts Payables tumbled by 66.09% in 2023 and then spiked by 73.19% in 2024.
  • Quarterly analysis of 5 years shows Puma Biotechnology's Accounts Payables stood at $11.2 million in 2021, then plummeted by 42.37% to $6.4 million in 2022, then climbed by 6.97% to $6.9 million in 2023, then dropped by 20.03% to $5.5 million in 2024, then fell by 14.96% to $6.4 million in 2025.
  • Its Accounts Payables stands at $6.4 million for Q3 2025, versus $5.4 million for Q2 2025 and $6.0 million for Q1 2025.